This Could Be the Biggest Stock Market Winner… EverTravis what do you think – from Luke Langos teaser on Quantum Computing. I have a view but wondering if this is something you are looking at.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Any luck on finding this out? I Am a subscriber to one of his services but not his latest offering which is in the $1500 range
Haven’t looked at it yet, do you have a copy of the ad?
https://orders.investorplace.com/?cid=MKT565275&eid=MKT571957&encryptedSnaid=93narv1t5jPd%20nkqBkmTVBMZGk4O8%20Py1jxX%20f8YH70%3D&snaid=SAC0008002725&step=start&emailjobid=5010713&emailname=082821_MESI_3PM_Buy&assetId=AST196683&page=1
See above – might be worth looking at AXE on the ASX
https://www.google.co.uk/amp/s/www.nasdaq.com/articles/quantum-computing-could-produce-the-biggest-stock-market-winner…-ever-2021-08-12%3famp
It’s IonQ which will be going public via a reverse merger with a SPAC called dMY Technology Group, Inc. III (NYSE: DMYI).
Thanks for sharing. It looks like an interesting company and one with huge potential. Unfortunately, I am too impatient to wait something like this out (3-5 years without any meaningful revenue). If they start to deliver on promised might be one to add later.
Did you catch any of his other 7 or 8 stocks in his 1 to 30 Wealth Summit?
His original giveaway was ASTS up 40 % in 2 weeks.
His latest addition he just teased I THINK is Latch (LTCH) ???
Yes, I think you’re right. I also thought his latest tease was Latch (LTCH). I’m 98.3% sure.
Just the free pick, ASTS.
I didn’t renew my Early Stage Investor subscription back in June when it was up for renewal because I have stock picks oozing out every orifice right now and I simply can’t buy them all.
Because of the quantum computing tease, I was able to figure that one out since IonQ is the best pure-play stock in the category and Luke Lango previously pitched it as one of his Daily 10X picks. So I knew he liked the stock.
I actually bought DMYI at $9.75. But then I sold it a couple weeks ago at $10.50. It’s the best return I’ve had on a SPAC since QuantumScape topped $130/share last December.
Ahhh, yes, those were the good ol’ days of irrational exuberance and excessive froth. That’s when I was also young and naive and thought SPACs wouldn’t ever go below $10.00/share. Now, they all drop like lead balloons to somewhere between $4.00 and $8.00 after they de-SPAC and have been the bane of my portfolio.
So I plan to buy back into IonQ after it de-SPACs and starts trading under $7.00/share.
Another of the 1 to 30 Early Stage Investor picks is LiDAR company AEVA.
Very interesting! Thank you for the info. AEVA was Luke’s Daily 10X pick on December 7 of last year when it was still a SPAC with IPV and trading at $12.50/share. Back then, he thought it would only 20X over the next decade. Now, it’s trading around $9.50 and apparently has 30X potential. Since I already own AEVA, it’s great to know that Luke still has strong conviction for this stock.
It was also a buy recently in his Innovation Investor in March/April. Like some of these other services with multiple pitches, a lot of the picks just get repackaged. Especially prevalent with LL since he has his daily 10X pick as well.
Are you sure it was Innovation Investor? I also have a subscription to that service, and I’m not seeing it. LAZR and OUST are in there, but not AEVA. Of course, with Luke running so many of the services at InvestorPlace now, it’s hard to keep them all straight, especially when there’s a bunch of overlapping stock picks across the services.
I believe so (but can’t find it now). It was not a formal “buy”, but just discussed in one of his periodic reports (which now don’t seem to occur nearly as frequently – just sales pitches to the other services).
Travis,I’ve been trying to get e-mails on comments made by members on Mampilly’s season2 and season 3 but I haven’t had any luck , what am I doing wrong?
You are subscribed to those threads, and our system indicates that the emails are being sent and aren’t being opened, so they’re probably being blocked. I suspect AOL is probably blocking some of your emails, we see this pretty regularly with aggressive spam filters.
Any ideas on Lukes latest tease. “small protein sequencing startup using proteomics-on-a-chip platform”. I think it might be Quantum-Si (QSI). Recently listed via a SPAC.
#Lango #QSI
Yes, you guessed right. It is indeed QSI.
Thanks for the confirmation. He seems to be teasing a few of his 1 to 30 listings.
Travis, here’s the teaser on Luke Lango’s latest teaser:
Brought to you by INVESTORPLACE
If You Missed the Genomic Revolution, Now Is Your Chance to Get in on the Proteomic Revolution!
Have you seen gene editing and sequencing stocks recently?
Illumina (ILMN) is up 20% over the past three months. Beam Therapeutics (BEAM) is up 45%. Editas Medicine (EDIT) is up 90%. Intellia Therapeutics (NTLA) is up 150%.
Folks, the Genomic Revolution is here.
And while everyone can see those big gains and be impressed, what most investors miss is that the seeds for this Genomic Revolution were planted about 20 years ago, when the gene sequencing industry underwent an enormous technological breakthrough called Next Generation DNA Sequencing (or NGS).
Long story short, the “old school” way of sequencing DNA was accomplished through gene-by-gene analysis. Each gene had to be analyzed and sequenced by itself. Of course, this was an exceptionally time- and labor-intensive process that stymied the mapping of the human genome for decades.
Then, in 2000, a small company by the name of Lynx Therapeutics launched the first NGS technology, which enabled massively parallel DNA sequencing. That breakthrough hit the fast-forward button on the Genomic Revolution.
Three years later, the Human Genome Project was finished (after a decade of minimal progress). About a decade later, CRISPR-Cas9 gene editing systems entered the equation. And 20 years later, we are where we are today, with multiple multi-billion-dollar gene editing and sequencing companies on the cusp of fundamentally changing biology forever.
Fun fact: That small company, Lynx Therapeutics, was acquired by Solexa, which was eventually acquired by Illumina – which, today, is a $70 BILLION gene sequencing giant.
And it all started 20 years ago, with the invention of parallel DNA sequencing technologies.
Alas, why am I telling you all of this?
Because while next-gen DNA sequencing technologies were invented 20 years ago, next-gen protein sequencing (NGPS) technologies are being invented right now. And, just as NGS tech kickstarted a multi-hundred-billion-dollar Genomic Revolution that resulted in multiple 10X winners in the 2010s, NGPS tech will kickstart an equally large Proteomic Revolution that will result in multiple 10X winners in the 2020s.
To understand why the Proteomics Revolution will be just as big as the Genomics Revolution, we need to take a quick trip back to our college biology class.
Do you remember the central dogma of biology? It’s the fancy term used to describe the flow of information in the biological world.
Long story short, information is first encoded as DNA (our genes). It then goes through a process called “transcription” and turns into RNA. As RNA, information then goes through a “translation” process to turn into proteins.
Basically, you go from DNA to RNA to proteins. Genes are the starting point. They tell you what could happen. Proteins are the destination. They tell you what is happening.
That’s why proteomics is such an important field.
Not to mention, with each step of the process, things get a bit more complex. That is, each DNA strand can turn into multiple RNA strands, which can turn into multiple proteins. This results in there being just about 20,000 genes in our genomes, but about 200,000 transcripts and over 1,000,000 proteoforms in our proteomes.
So, while genomics does tell you a lot about the biological makeup of a living thing, it’s far from a complete picture. Rather, proteomics actually paints a fuller picture of someone’s biological makeup. And, together, proteomics and genomics do paint a full picture.
It is this marriage of proteomics and genomics that researchers believe will create the foundation for humans to forever eradicate disease.
That’s a big deal. How do we get there? Well, genomics is well on its way, thanks to NGS technologies. Proteomics, however, still has a long way to go – because it’s relying on old-school analog protein sequencing technologies.
But that’s all changing right now, thanks to one small protein sequencing startup that is doing today what Lynx Therapeutics did 20 years ago. It is ushering in a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.
And it’s doing so in an especially innovative way – by marrying semiconductor technology with biology to create a next-gen proteomics-on-a-chip platform that is automatable, cost-effective, and highly scalable.
This platform represents the future core technology of the Genomic Revolution. And this company is the next Illumina.
That’s why we just unveiled the name, ticker symbol, and key business details of this game-changing biotech startup in The Daily 10X Stock Report – our ultra-exclusive investment research advisory aimed at giving you a fresh 10X stock pick every single day the market is open.
We launched the service just a year ago. In that year, we’ve scored nearly 100 peak triple-digit winners and have identified six different stocks that have soared 10X or more in value.
It’s been a fun ride… but things are just getting started…
Join us now, plug into the Proteomics Revolution, and get the name of the next Illumina by clicking here.
Sincerely,
Luke Lango
Editor, MoneyWire
On the date of publication, Luke Lango did not have (either directly or indirectly) any positions in the securities mentioned in this article.
It’s Quantum-Si (QSI).
Thanks @Luckin Enron (love the ironic name!) you are great some of us can’t afford some of these subscriptions much appreciated!
investor place with Eric Fry and Louis Navellier- is it a fraud
I also was interested in quantum computing stocks, but my research wasn’t answering the questions I needed answered in order for me to make the investment decision. I sent an email to my cousin’s son who is brilliant, all things computers and an engineer at Amazon. I made my decision, based on his responses, to hold off investing in this tech. He’s not overly familiar with the technology, but he checked with a friend who is doing her post-doc in quantum computing at a highly respected west coast university. She didn’t give a favorable response. The questions are mine and the answers are his.
1. Is quantum computing the way of the future?
A. Mostly no. It will have its applications eventually, but it won’t be revolutionary for the common person. Currently we have our laptops and phones, and scientists have their supercomputers in data centers. Quantum computers will likely exist only in supercomputers for the foreseeable future. I would actively bet against there being a quantum-computing-enabled consumer device that you or I could purchase in our lifetimes.
2. How many years down the road do you see it becoming relevant?
A. It will potentially become a more-useful thing for scientists in the next 5-10 years, I would guess. But again, I don’t anticipate it being something that you and I would have any use for, let alone could afford. So, I don’t see there being a market.
3. Do you think that investing in this technology (not this specific company) at this time is a wise thing to do?
A. Personally, I would not invest in the tech. I don’t know enough about it, but I don’t see how it could be profitable in the near future.
I’m not trying to sway anyone’s thinking or decision making, but I want potential investors to have additional information for their DD. Good luck to all!